Herbal Products Regulatory Services – EU & UK Traditional & Herbal Medicines

End-to-end regulatory support for herbal medicinal products across Europe and the United Kingdom. We guide companies through the two available pathways for bringing herbal remedies to market  Traditional Herbal Registration (THR) for long-established remedies and full Marketing Authorisation (MA) for well-documented herbal medicines  ensuring each product meets the quality, safety, and evidence requirements. Directive 2004/24/EC on traditional herbal medicinal products has been fully transposed in almost all European member states since 2007, introducing a new pathway for marketing and licensing traditional herbal medicines. Under this legislation, a company is required to show the quality, safety and efficacy of their herbal medicinal products by demonstrating traditional use within the EU for at least 15 years and at least 30 years outside the EU, and the herbal medicines must now be manufactured under GMP conditions. Whether navigating a THR in the UK or pursuing a well-established herbal Marketing Authorisation in Europe, our team prepares inspection-ready dossiers and compliance systems that stand up to regulatory scrutiny.

This service is suitable for:

• Herbal Medicine Companies & Supplement Manufacturers: Firms producing herbal remedies who need to transition from selling as unlicensed supplements into the regulated medicinal space, or new entrants developing herbal treatments that require formal approval. We assist small and mid-sized companies lacking in-house regulatory departments to obtain Traditional Herbal Registrations (THRs) for products used in minor conditions (e.g. herbal cough medicines, sleep aids, digestive remedies) or full Marketing Authorisations for herbal medicinal products with well-established efficacy. The herbal medicines can be approved for marketing either through a Traditional Herbal Registration (THR) or a Marketing Authorisation registration (MA). If you currently market a product as a food supplement but it is making implicit medicinal claims (e.g. “relieves pain” or “treats anxiety”), you likely need to register it as a medicine – we help determine the correct classification and pathway.

• Traditional Medicine Producers (EU/UK & International): Companies outside the EU/UK with traditional herbal formulations (Ayurveda, Traditional Chinese Medicine, etc.) seeking entry into European markets. We provide local regulatory support and prepare the evidence required to satisfy European regulators of the product’s traditional use – a minimum of 15 years in the EU and 30 years outside the EU for THR eligibility. By navigating both EU and post-Brexit UK requirements in parallel, we streamline multi-jurisdictional launches.
• Pharmaceutical Companies Adding Herbal Lines: Established pharma companies diversifying into herbal OTC products or well-established herbal actives (e.g. standardised ginkgo extracts, thyme syrups, ivy leaf cough remedies). We offer specialist expertise in herbal Module 3 (Quality) challenges like plant extract standardisation and stability and ensure alignment with HMPC (Committee on Herbal Medicinal Products) monographs and existing EMA assessment reports when available. This service ensures your herbal product dossiers meet the same rigorous standards as conventional medicines, ready for agency inspection or audit.
• Cosmetics/Food Businesses Exploring Medicinal Claims: Companies in the cosmetics or health food sectors who plan to make disease or treatment claims for botanical products. If you intend to market a topical herbal cream or a botanical supplement with therapeutic claims, you step into medicine territory. We help such businesses pivot to the medicinal product regulatory route legally and efficiently or advise if staying in the food supplement or cosmetic category is more appropriate (with adjusted claims).

This service may not be the right fit if:

• You want to market herbal products only as food supplements or cosmetics with purely nutritional or cosmetic claims and no implied medicinal use (in those cases we can advise on general regulations, but our licensing service is focused on medicinal registration).
• Your product contains non-herbal active substances or potent components that would classify it as a conventional pharmaceutical (those require a standard medicine MA rather than the herbal/traditional pathways).

Choosing the Right Pathway (THR vs Full MA): Herbal products can be registered via two routes: the Traditional Herbal Registration (THR), which waives the need for new clinical trials provided you can demonstrate at least 30 years of traditional medical use (15 of them within the EU) for the product’s ingredients; or a Well-Established Use / Full Marketing Authorisation, which treats the herb like any medicinal active and requires substantial evidence of efficacy (but often allows reliance on published literature if the ingredient’s efficacy is well established in the EU). Choosing incorrectly can waste time and money for example, applying for a full MA when a THR would suffice (or vice versa). We guide you in assessing the product’s claims, evidence, and intended patient population to select the most viable route.

Gathering Traditional Use Evidence & HMPC Support: For THR, the burden is proving longstanding use and safety rather than conducting new clinical trials. We help compile the necessary historical evidence: bibliographic literature, pharmacopoeial references, and any available safety data to satisfy regulators that the product has an acceptable level of safety and plausible efficacy claims based on traditional use. We also leverage HMPC monographs (if available for the herbal substance), which often summarise pharmacological information and traditional uses accepted at the EU level. A challenge arises when a product’s formula or indication slightly diverges from documented traditional uses – we formulate bridging arguments or minor reformulations to fit within accepted parameters, reducing the risk of registration refusal.

Quality and Manufacturing Compliance for Botanicals: Herbal medicines face unique CMC (Chemistry, Manufacturing, Controls) challenges: batch-to-batch consistency of herbal extracts, presence of impurities like pesticides or heavy metals, and meeting Good Manufacturing Practice (GMP) for what are often food-grade facilities. Regulators require that herbal medicinal products be manufactured under pharmaceutical GMP conditions. We assist manufacturers in upgrading or documenting their processes to meet EU and UK GMP standards (aligning with EU Guidelines on Herbal Drug Preparations and relevant pharmacopoeial quality tests). We also anticipate stability study requirements (e.g. proving a herbal tea or tincture remains within specification over shelf life) and help design those studies. This prevents the common pitfall of quality-related deficiencies during assessment.

Borderline Product Decisions: Many herbal products straddle regulatory categories. Is a vitamin-rich herbal tablet a medicine or a supplement? Is a tea for digestion a food or a herbal remedy? We perform borderline assessments to determine if your product’s composition and claims push it into the medicinal realm. For example, adding a health claim like “relieves joint pain” makes a product a medicine in the EU definition, even if it is formulated as a food supplement. Conversely, a herbal product without medicinal claims might be sold as a supplement, but then it cannot have any disease-related indications on its label. The MHRA has issued guidance (“A Guide to what is a Medicinal Product”) and in case of doubt, advice may be sought from the MHRA’s Borderlines Section. We map out the consequences of each classification (regulatory requirements, marketing freedoms, distribution channels) so you can decide. If a product is better suited to remain a supplement or cosmetic, we advise accordingly and adjust claims to ensure compliance outside the medicines regime. If it needs to be a medicine, we help you avoid regulatory circumvention that could lead to enforcement actions.

Synchronising EU and UK Submissions Post-Brexit: If you want your herbal product available across Europe and the UK, you now face dual processes. The EU’s traditional use registration is a national procedure in each member state (there is no mutual recognition specifically for THRs, though in practice many requirements are harmonised), and the UK has its own THR scheme under the MHRA. We develop a parallel submission plan: for example, compiling one core dossier that can be submitted to the HPRA in Ireland and the MHRA in the UK (and other agencies as needed), with only minor country-specific Module 1 differences. We also help manage duplicative obligations like separate pharmacovigilance systems or label translations. Without careful planning, companies can trip over subtle differences  e.g. the UK requires a UK-based contact for pharmacovigilance and its own notification, while the EU might have different submission formats (CESP vs national portals). Our service anticipates and aligns these to avoid regulatory snags.

Post-Registration Commitments & Monitoring: Obtaining the registration is not the end – herbal products are subject to pharmacovigilance and periodic review just like conventional medicines. We prepare clients for ongoing obligations: for instance, periodic safety update reports (PSURs) may be required at defined intervals for herbal MAs, and the MHRA or EU authorities may ask for specific post-registration studies if any safety concerns exist (though rare for traditional use products). Companies unfamiliar with medicine regulations can struggle here (e.g. failing to report adverse reactions or to update labelling when new safety information arises). Our integrated pharmacovigilance support ensures you continue to meet all expectations after your product is on the market, keeping your hard-won registration in good standing.

Regulators in the EU and UK apply the same fundamental standards to herbal medicines as to any other medicinal product, with some accommodations for traditional use. Here are the core expectations:

• Demonstration of Quality, Safety & (Traditional) Efficacy: Whether via a full Marketing Authorisation or a Traditional Herbal Registration, a herbal product must meet quality and safety standards and have a plausible efficacy rationale. For THRs, Directive 2004/24/EC requires that the applicant show at least 15 years of traditional medicinal use within the EU (and 30 years total worldwide) for the ingredients. This serves as a surrogate for clinical efficacy evidence. You must compile bibliographic proof that the herb has been used for the intended indication for decades and include any safety information (or lack of serious safety signals) observed in that time. For well-established use MAs, published scientific literature demonstrating efficacy over a substantial period in the EU is needed to qualify. In all cases, regulators will not accept untested novel herbal combinations with no tradition or evidence – those would either require new clinical trials or be rejected as lacking basis.
• Full CTD Dossier & GMP Compliance: Herbal medicines are subject to the Common Technical Document (CTD) format for the application dossier. This means providing detailed Modules 3 (Quality), 4 (Non-clinical), and 5 (Clinical) or their literature-based equivalents. The quality section must show control of starting plant materials, consistent manufacturing (extraction processes, batch analytics, stability data) and adherence to pharmaceutical GMP. The legislation explicitly requires that herbal products be manufactured under GMP conditions, just like any conventional drug, to ensure purity and consistency. The non-clinical and clinical modules for a THR largely consist of literature reviews; for a full MA, they may include new data or formal references to studies. Even if new efficacy trials are not required for THR, you still need to address basic pharmacology and toxicology (e.g. does the herb have known organ toxicity? any carcinogenicity concerns from constituents?). The HPRA, MHRA, and other agencies scrutinise these modules to confirm there are no gaps (like an unqualified impurity or insufficient stability testing).
• Appropriate Classification & Labelling: Authorities will verify that your product is correctly classified and not positioned under the wrong rules. If you apply for a THR, your product must meet the definition of a traditional herbal medicinal product: indications suitable for self-medication without doctor supervision, usually mild conditions, and exclusively herbal active ingredients (vitamins or minerals may be included only if they contribute to the efficacy of the herbs, not merely as supplements). If your product contains non-herbal actives, it cannot use the THR route. Similarly, if your product’s claims are more serious than allowed for self-care (e.g. “treats depression” or “cures infection”), regulators may object that it is not suitable for THR classification. They expect that THR product literature includes the required disclaimer: for example, “Traditional herbal medicinal product for [indication] exclusively based upon long-standing use.” For full MAs, they expect claims to be supported by evidence and consistent with well-established uses or clinical studies. In all cases, the product’s Summary of Product Characteristics (SmPC), labelling, and patient leaflet must comply with template guidelines (including specific sections for traditional use, if applicable). Products that are intended to be ingested, inhaled, injected or implanted in ways inconsistent with the cosmetic definition are not classified as cosmetic products – similarly, products making medicinal claims cannot be sold as food supplements.
• Pharmacovigilance and Responsibility: Once on the market, herbal medicines are subject to pharmacovigilance monitoring like any medicine. Regulators expect that you, as the Marketing Authorisation Holder (or THR holder), have a system to collect and evaluate adverse reactions. Even “natural” products can have side effects or interactions, and authorities will not accept neglect of PV duties. For example, if a serious adverse reaction is reported with your product, you are expected to assess it and report it through the appropriate channels (e.g. the EU’s EudraVigilance database or the UK’s MHRA Yellow Card scheme). Regular safety updates (PSURs) may be expected, typically at intervals determined by a reference list or as specified by authorities. The MHRA has an inspectorate that can audit companies for pharmacovigilance compliance even for THR products. Thus, regulators expect that from the day of placing the product on the market, you maintain MAH responsibilities, including a Qualified Person for Pharmacovigilance (QPPV) and a Pharmacovigilance System Master File (PSMF), proportionate to the size of your company. We ensure these are not overlooked.
• No Overlap with Other Regulatory Regimes: Regulators will cross-check that your herbal product is not simultaneously, or inappropriately, marketed under another regime. For instance, it is not acceptable to sell essentially the same product as a “food supplement” in one channel and a “herbal medicine” in another with medicinal claims – that could be seen as an attempt to circumvent medicines law. If your product is registered as a herbal medicine, any versions of it in the market must comply with medicines rules. Conversely, if you decide to keep it as a supplement or cosmetic, you must refrain from medicinal claims. Enforcement bodies (like Trading Standards in the UK or regulatory authorities in EU states) actively monitor such borderline infractions. We help ensure your product’s presence in the market is internally consistent and defensible under the chosen category’s rules.

We provide a structured approach to take herbal products from concept or supplement status through to fully compliant medicinal product registration and beyond. Our model covers strategic planning, dossier development, authority interaction, and ongoing compliance.

At project kick-off, we conduct a thorough analysis to craft the optimal regulatory strategy:

• Product Classification & Claims Review: We examine your product’s formulation, intended use, and marketing claims. If your goal is to make disease or health claims that trigger medicine status, we confirm that the product qualifies as an herbal medicinal product (e.g. all active ingredients are botanical or naturally occurring substances). We identify if any component might cause classification issues  e.g. a high-dose vitamin included for general health might reclassify a “herbal” product as a supplement, unless it also has a therapeutic role in the traditional remedy. We provide clear advice: proceed with THR/MA as a medicine, or adjust the product/claims to fit a different category if that is more viable.
• Pathway Decision (THR vs MA vs Food/Other): Based on the product and your commercial objectives, we recommend the appropriate pathway:
  • If the product meets traditional use criteria (long history, appropriate indication, safety profile), we often lean towards Traditional Herbal Registration as it is faster and less resource-intensive (no new clinical trials). We outline the evidence needed and any limitations (e.g. marketing under THR requires specific labelling like “traditional use” and cannot mention new scientific claims).
  • If the product has robust scientific data or addresses conditions needing well-established use/MA route (or you seek broader claims that a THR cannot support), we strategies a full Marketing Authorisation application. This may involve leveraging published studies to avoid new trials.
  • If we determine a medicinal route is not feasible or necessary, we advise on staying within the food supplement regime, perhaps with softer health claims, or classify as a cosmetic for topical products with non-medicinal intent. (In such cases, we can still assist via our other services, but we ensure you make an informed decision.)
• Regulatory Roadmap & Liaison Plan: Once the path is set, we develop a roadmap with key milestones (data gathering, dossier drafting, submission, anticipated approval timelines). We also identify relevant regulatory contacts: for THRs, this might be national agency units like the MHRA’s Traditional Herbal Medicines Registration Unit or the HPRA’s herbal medicines section; for full MAs, possibly EMA’s Herbal Medicinal Products Committee (HMPC) involvement for guidance. We map out opportunities for coordination among countries – for example, compiling one core dossier that can be submitted to multiple national agencies with only minor country-specific Module 1 differences.

For products following the THR route, we manage every component of the registration process:

• Assembling Traditional Use Evidence: We gather all documentation of the product’s medicinal use. This includes reviewing medicinal plant monographs from the HMPC or national pharmacopoeias, searching scientific literature and ethnobotanical texts, and compiling any available sales or medical records that demonstrate at least 30 years of use (with 15 in the EU) for the ingredient or combination. We pay attention to indication matching ensuring the historical use cited is for the same or very similar indication as what you propose. If your product is a fixed combination of herbs, we document traditional use for that exact combination (if available) or each component separately plus evidence they have been used together. We then write the Herbal Traditional Use Overview section that authorities heavily scrutinise in THR applications.

• Dossier Preparation (THR-specific): We compile a CTD-like dossier, with adaptations for THR:
  • Module 1 (Administrative): We prepare national application forms for each target country. We construct Module 1, including writing of the SmPC, product labelling and Patient Information Leaflet (PIL) texts. We ensure the PIL includes the standard phrase appropriate to the indication and the statement that the product is a traditional remedy for a certain use.
  • Module 2 (Overviews & Summaries): We author an Expert Report/Overview specifically focused on traditional use and safety. We include a Quality Overall Summary (QOS) highlighting herbal-specific quality aspects.
  • Module 3 (Quality): We compile full pharmaceutical data. This includes plant raw material specifications (e.g. botanical identification, assay of key constituents), validation of extraction processes, finished product specifications (assay of active markers, microbiological purity, contaminant levels, etc.), stability data under ICH conditions, and if applicable, bracketing/matrixing data for multi-herb products. We leverage any pharmacopoeial monographs (e.g. European Pharmacopoeia monograph on your herbal drug or extract) to ensure specifications meet official standards.
  • Modules 4 & 5 (Safety and Efficacy): Instead of new studies, we provide summaries of published data: any toxicology studies on the herb (acute, chronic toxicity, genotoxicity), any known contraindications from medical literature, and a clinical summary of its use (even if mostly observational data). We also include an assessment of safety in special populations (children, pregnancy – often leading to warnings like “Not recommended under 18 years” unless tradition supports paediatric use).
• Submission & Liaison: We submit the application to the target national authority (or multiple in parallel). Our team then acts as your representative in all communications. We handle clarification requests or List of Questions from regulators. For instance, if the MHRA asks for clarification on whether the 15-year EU use is fulfilled, we provide the needed references or market data. If any quality deficiencies are cited (common in herbal submissions: e.g. need for tighter control of batch variability), we work with your manufacturers to resolve them and provide the answers. Our familiarity with the typical concerns of herbal evaluators allows us to pre-empt many questions or answer them effectively.
• Approval & THR Certificate: Upon a successful assessment, you receive a THR certificate (in the UK) or national registration number. We review the final product information issued by the regulators to ensure accuracy. We also guide you on the correct usage of the THR certification mark and number on packaging. This final step sets the stage for product launch.

For herbal medicines that pursue a full Marketing Authorisation (when, for example, stronger claims or broader uses are desired, or the product includes non-herbal actives), we follow a more data-intensive process:

• Gap Analysis of Required Studies: We assess what evidence exists and what might be missing. Well-established use applications rely on published literature to demonstrate efficacy and safety. We perform a literature search to ensure clinical use in the EU is documented for the active, including controlled trials or meta-analyses if available. If key data are lacking (say no published long-term safety for a certain condition), we flag that risk. In some cases, a hybrid approach (combining literature with a bridging study) might be needed – we advise if you should conduct a small clinical study or a bioavailability study to shore up the dossier.
• CTD Dossier Authoring (MA): We prepare a full Module 2 set: Quality Overall Summary, Non-clinical Overview/Summary, Clinical Overview/Summary. Unlike THR, a full Clinical Overview must provide a detailed benefit-risk assessment. Our medical writers include data from randomised trials if available. We handle construction and writing of CTD Modules 2, 3, 4 and 5. If no comprehensive clinical trial exists, the Clinical Overview will argue efficacy based on consensus of historical evidence and any smaller studies, plus well-established use rationale accepted in the EU (sometimes reflected in an HMPC monograph which, while not binding, carries weight).
• Regulatory Interactions: For a full MA, particularly via decentralised or mutual recognition procedures (if you seek approval in multiple EU countries based on one application), we handle the more complex coordination. We might recommend a Scientific Advice meeting with an authority if your approach to demonstrating efficacy is unusual. During assessment, authorities may have tougher questions on clinical aspects than in a THR. We prepare robust response documents with additional analyses or justification as needed.
• Licence Grant & Post-approval: After approval, the product will have a standard Marketing Authorisation valid typically for five years initially (with the option to become unlimited in duration thereafter). We ensure you understand any special conditions  e.g. sometimes a Risk Management Plan (RMP) might be required if there is a safety concern with one of the herbal constituents. We also set up your pharmacovigilance if not already in place (see below). Additionally, if this was via an EU procedure, we coordinate the national phase tasks like translating labelling into various languages, which is required for each country before you can market there.

Many clients come to us unsure if their product should be a medicine at all. We incorporate a formal borderline assessment step in our process:

• Review of Ingredients & Intended Use: We create a comparative table of your product’s ingredients, doses, route of administration, and the claims you want to make. We then compare this to regulatory definitions:
  • Medicinal Product – defined by presentation (claims) or function. If your labelling or market materials suggest treatment or prevention of disease, or if the product has a pharmacological effect capable of significantly restoring or correcting physiological functions, it falls under the medicines scope.
  • Food Supplement – regulated under nutrition laws as concentrated sources of nutrients or other substances with a nutritional or physiological effect, intended to supplement diet. No medicinal claims are allowed; only general health or permitted nutrition claims.
  • Cosmetic – per Regulation (EC) No 1223/2009, a product applied to external parts (skin, hair, etc.) with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition, or correcting body odours, without claiming to treat diseases.
• Regulatory Decision Document: We deliver a clear recommendation document. For example: “Product X with claim ‘relieves mild anxiety’ is unequivocally a medicinal product – it should go through THR. Product Y, a chamomile tea labelled for general wellbeing with no disease claims, can be classified as a food provided it stays within supplement dosages and avoids health claims beyond what is allowed.” We highlight any grey areas. If you prefer to stay non-medicinal, we might advise reformulating or rewording claims to fit, and we can coordinate with our Quality/Compliance team to ensure you still meet food/cosmetic standards. If proceeding as a medicine, this analysis feeds into the above strategy to ensure no missteps.
• Liaison with Regulators on Classification: In tricky cases, we can approach regulators (via written queries or meetings) for a formal classification opinion before you invest in a full application. For instance, the MHRA offers a borderline advice service; we prepare the briefing package and question for them. Having clarity that, say, “Yes, MHRA confirms this product is considered a medicine and should have a THR” can de-risk your project. Conversely, if they determine it is a food supplement, you save the effort of a THR and instead meet the food regulations. We include such interactions in our service as needed.

Dossier Preparation, Reviews & Gap Analysis

Preparing a high-quality application dossier is our core execution task. This spans writing new content, reviewing client-provided drafts, and ensuring nothing is missing:

• Authoring Key Documents: Our team writes all required CTD Modules and supporting documents as outlined under the chosen pathway. Pharmafile’s listed services for herbal products include construction of Module 1 (SmPC, product labelling and PIL texts), performance of Readability User Testing, generation of Braille, and construction and writing of CTD Modules 2, 3, 4 and 5. We also prepare annexes like a mock-up of packaging for artwork review. For all medicine cartons in the EU, Braille for name and form is required – we coordinate getting Braille added to artwork files.
• Quality Control & Peer Review: Before any submission, we perform rigorous QC. A second regulatory expert checks that all consistency points align (ingredient names, concentrations, indications are identical across forms, SmPC, and summaries). We verify that all claims in the overview are substantiated by data somewhere in Modules 3-5 or in literature references. If we took an internal draft from your team, we incorporate it and refine it, ensuring it is phrased in the regulator’s expected style. Our internal checklists for herbal submissions – which cover common omissions like ensuring proof of EU presence for 15 years, including manufacturing flow-charts, providing safety statements for use during pregnancy – help catch issues that could otherwise result in regulator questions.
• Addressing Data Gaps: Often during dossier assembly we identify a missing piece of evidence or an insufficient justification. Rather than leaving it for regulators to find, we act immediately:
  • If a phytochemical marker assay is missing, we work with your lab to obtain results or at least have justification ready for why it is not needed.
  • If there is no data on use in children but the product could conceivably be used by teenagers, we either craft labelling to exclude under-18s or provide a rationale from traditional use that it was not used in children historically.
  • If heavy metal testing was not done on three batches, we might include a commitment to test the next production batches (regulators often accept such post-registration commitments for THRs). We essentially simulate the regulatory evaluation in-house to pre-empt deficiencies.
• Compilation in eCTD/VNeeS Format: Once documents are final, we compile them in the required electronic format. For full MAs, we use eCTD (electronic Common Technical Document) format and validate the sequence to ensure it will pass agency technical checks. For purely national THRs, some agencies might accept a simpler format, but increasingly even THRs are submitted via CESP (Common European Submission Portal) in CTD format. We handle all technical aspects, so you get a seamless submission without wrestling with dossier publishing software. If needed for a national procedure, we also produce specific file formats required by individual agencies (e.g. the MHRA portal requires certain PDFs; Irish submissions go via CESP in CTD structure).

After securing the registration, we offer ongoing support to maintain compliance and handle regulatory obligations throughout the product’s lifecycle:

• Pharmacovigilance System Setup: We establish a proportionate PV system for your herbal product. This includes:
  • Designating a Qualified Person for Pharmacovigilance (QPPV) (for EU, and a local UK QPPV or UK PV contact for Great Britain) and ensuring continuous contact availability.
  • Preparing a Pharmacovigilance System Master File (PSMF) that describes how you monitor and report safety. For a small herbal company, the system might be scaled down, but regulators still expect processes for handling adverse events, signal evaluation, and periodic reporting.
  • Training your staff (or establishing a contract with us) to report any adverse reaction – even if something as simple as a consumer email that “this remedy gave me a rash,” it must be documented and assessed.
  • We can serve as your outsourced PV department, collecting any adverse events, performing causality assessments, and submitting expedited reports if a serious reaction occurs. We also prepare Periodic Safety Update Reports (PSURs) at required intervals.
• Renewals and Variations: In the EU and UK, a Marketing Authorisation or THR is typically granted for five years initially. We manage the renewal application at the five-year mark, compiling an overview of safety and any changes since approval to demonstrate the benefit-risk remains positive. After renewal, licences can become of unlimited duration; the MAH can confirm to the agency that they wish the marketing authorisation to become unlimited in duration, and no assessment is involved in this administrative step. We also handle variations (post-approval changes): whether it is adding a new manufacturing site, changing the herbal extract supplier, updating the PIL with new safety information, or even extending the indication (if evidence supports it). We categorise the variation (minor variations not requiring assessment, or those requiring assessment) and prepare the necessary documentation. For example, if you want to change your tablet’s excipients, we file a variation with revised Module 3 data and justification that it does not affect quality or efficacy.
• New Markets & Mutual Recognition: Once you have an initial registration in one EU member state (for a herbal MA), you may want to extend it to others. We support Mutual Recognition Procedure (MRP) if applicable. For THRs, while formal MRP is not available, we coordinate parallel national filings to replicate success efficiently. If you obtained a THR in Ireland and want one in Germany, we prepare the application referencing the Irish dossier and handle any required translations or minor national adjustments. Our familiarity with multiple agencies’ nuances can expedite these rollouts.
• Ongoing Compliance Audits: We periodically audit your processes (manufacturing changes, PV records, labelling compliance) to ensure continued adherence. If guidelines or regulations update – e.g. if a previously allowed herb gets a new restriction – we alert you immediately and help implement required changes proactively rather than waiting for authorities to mandate them.
• Support During Inspections: Herbal manufacturers and MAHs can be inspected for GMP or PV compliance. We provide inspection readiness support. For GMP, our Quality Services experts ensure your facility (or your contract manufacturer) is prepared, with documentation in order. For PV inspections, we ensure the requested evidence (like SOPs, case logs, training records) is readily available and accompany you through the process. Knowing that inspectors may focus on areas like identity of plant materials, pharmacovigilance for OTC products, or advertising compliance for herbal meds, we help you anticipate their concerns.

This ongoing support is optional yet highly recommended for companies new to the pharmaceuticals regulatory world, as it helps avoid inadvertent non-compliance after launch (for instance, forgetting to submit a variation for a formulation tweak, or missing a PSUR deadline).

Our herbal products service covers regulatory requirements in all major European jurisdictions, with tailored expertise for each:

• United Kingdom: We handle MHRA applications for both Traditional Herbal Registrations (THR) and full Marketing Authorisations in Great Britain (England, Scotland, Wales), and parallel Northern Ireland The UK’s THR scheme closely mirrors Directive 2004/24/EC: products carry a THR number and the traditional use disclaimer in labelling. Pharmafile can help clients to register their herbal medicinal products in the UK. We ensure compliance with any UK-specific post-Brexit requirements (e.g. submitting via the MHRA portal, including UK-oriented pharmacovigilance contacts). If a product will be sold in Northern Ireland, it follows EU rules (due to the Northern Ireland Protocol/Windsor Framework). We manage NI as part of the EU submissions, while ensuring GB has its separate MHRA process – effectively running dual compliance so you can cover the whole UK.
• Ireland & Other EU Member States: We manage national herbal registrations or MAs in any EU country. Starting with Ireland (HPRA), where Pharmafile is based, we have deep experience in the Irish herbal medicines registration process. Pharmafile can register herbal medicinal products in Ireland or other EU countries. We extend to Germany (BfArM), France (ANSM), Spain (AEMPS), etc., each of which implements the EU Directive. If needed, we coordinate multiple national submissions simultaneously, or sequence them logically (e.g. get one reference registration then use it for mutual recognition if possible). Where EU procedures apply:
  • For a well-established use MA or a new herbal combination classified as a medicine, we can use the Decentralised Procedure (DCP) to obtain approval in several EU countries in one process, with one country leading the assessment. We serve as your DCP project manager and liaise with the Reference Member State agency.
  • For THRs, formal DCP is not available, but if there is an HMPC EU monograph for the herb, it helps harmonise what different states expect. We capitalise on that to reuse dossier content with minimal changes.
  • We ensure local language compliance for each country’s product information (we work with specialised translators for PIL/label text to German, French, etc.).
• Pan-European Insight: Because we operate across borders, we also provide strategic insight such as which country might be a more straightforward starting point. For example, the UK and Germany have historically handled large volumes of herbal registrations and have well-defined processes, whereas some smaller states might have less experience and slower timelines. We might suggest obtaining a THR in the UK and using that data to approach other countries’ authorities informally to facilitate their process.

Regulatory timelines for herbal medicinal products can vary depending on the chosen pathway and countries involved. Below is a general guide to typical durations for key steps, keeping in mind these are estimates and actual timings can differ:

Note: Well-prepared applications using existing HMPC monographs can sometimes move faster if the agency has seen similar products. We calibrate expectations based on current agency workloads.

The regulatory landscape for herbal products is littered with preventable mistakes that can derail an application or lead to compliance actions. Our experience ensures you sidestep these pitfalls:

• Misjudging the Product Category: A frequent error is claiming “It’s just a supplement, so we don’t need approval,” while simultaneously implying medicinal effects in marketing. This has led many companies into enforcement trouble  products pulled from shelves for making unauthorised medicinal claims. We prevent this by either fully committing the product to the medicines route (with proper approval) or sanitising its positioning to clearly be a supplement/cosmetic. If a product needs a THR, we push you to obtain it rather than risk action by regulators for selling an unlicensed medicine.
• Insufficient Traditional Use Evidence: Companies sometimes submit THR dossiers without robust evidence of EU usage, perhaps assuming an ingredient’s global popularity is enough. Regulators have rejected applications because the 15-year EU use criterion was not met (for example, if a herbal ingredient was widely used in Asia but only recently introduced in Europe). We thoroughly research and document EU usage or advise delaying application until the criterion is met. Likewise, failing to match the traditional indication is a pitfall e.g. trying to obtain a sleep aid indication when tradition only supports “mild anxiety relief”. We align the indication with the evidence to avoid regulator pushback.
• Quality Oversights (Herbal Specific): Common quality mistakes include: not characterising the active herbal substance properly (e.g. not specifying the plant part or extraction solvent clearly), inadequate control of batch variability, and lacking stability data because of assuming herbal teas are “just food”. We have seen applicants omit pesticide testing or heavy metal analyses – a red flag for assessors. By imposing pharma-grade quality checks upfront, we eliminate these deficiencies. Another frequent issue: not manufacturing under GMP – some herbal firms think food-grade is enough. Regulators will find this, and the registration can be refused or suspended. The legislation is clear that herbal medicines must be manufactured under GMP conditions.
• Overt Medical Claims on THR Products: Even after obtaining a THR, companies sometimes market the product as if it is clinically proven. For instance, implying that a traditional cold remedy “has been clinically proven to cure colds” this contradicts the “traditional use” basis and can lead to advertising violations. We guide your marketing team on the dos and don’ts of herbal product advertising: permissible phrases, use of the THR certification in marketing, and ensuring all claims remain within the allowed scope. This protects you from advertising sanctions and maintains trust with regulators that you are using the registration as intended.
• Neglecting Pharmacovigilance Duties: Some assume that because a product is “natural,” they can be lax on safety monitoring. This is dangerous. There have been cases where a traditional remedy caused rare liver injury – authorities expect swift reporting and action. We install the needed PV processes so you will not accidentally fail to report a serious adverse event or miss a safety signal. Not filing PSURs when required or not responding to safety alerts (like an authority warning on an herb’s interaction with medicines) can jeopardise your licence.
• Ignoring Regulatory Updates: Herbal medicinal regulations evolve – e.g. new HMPC monographs, or changes like Brexit requiring separate UK registrations. A company might continue selling with an EU THR in Great Britain post-2021, not realising that after Brexit they needed a UK-specific THR – risking enforcement. We keep track of such changes and transitioned clients through Brexit seamlessly, obtaining UK licences to replace EU ones as needed. We also monitor ingredient-specific rules: if the EU decides to restrict an ingredient due to safety (via an update or an EMA safety review), we alert you immediately and plan a reformulation or withdrawal if necessary, rather than waiting for a knock on the door.
• Inadequate Documentation of Manufacturing & Supply Chain: Herbal products often involve multiple suppliers (growers, extract manufacturers). A mistake is failing to maintain proper documentation from each source certificates of analysis, GMP certificates, supply chain traceability. Regulators or inspectors may ask for proof that the farm cultivating your herbs follows Good Agricultural and Collection Practice (GACP) or that the supply chain is secure against adulteration (a known risk with herbal raw materials). We help set up and document these quality assurance measures. Without them, approvals can be delayed or conditions imposed.

By consciously avoiding these mistakes through our proactive approach, our clients achieve faster approvals and maintain a clean compliance record, giving them a reputation as reliable providers of herbal medicines.

Integrating the Herbal Products service with our other offerings ensures a smooth journey from development to market:

• Regulatory Affairs Management (Human Medicinal Products): Many aspects of herbal product registration overlap with conventional pharma. Our core Regulatory Affairs service covers strategic planning, dossier submission, and agency negotiations for all types of medicines. Complex cases where a herbal ingredient might be part of a combination product, or where a borderline decision must be made (device vs medicine), benefit from our broader medicines regulatory expertise. (See our Regulatory Affairs Management page for full scope.)
• Pharmacovigilance Services: Once your herbal product is on the market, our Pharmacovigilance team steps in to manage adverse event reporting and safety oversight. This is crucial for herbal MAHs who may not have internal drug safety infrastructure. We provide EU QPPV services, set up your reporting database, and prepare PSURs. (Refer to our Pharmacovigilance Services page for details on our safety monitoring.)
• Quality & GMP Compliance: Herbal products can face GMP inspections for both the finished product and the raw herbal materials (which should be cultivated or collected under GACP – Good Agricultural and Collection Practice). Our Quality Services experts help ensure your supply chain, testing laboratories, and manufacturing sites meet the required standards. We can conduct vendor audits for your herbal extract suppliers and assist in obtaining Manufacturer’s Authorisations if you need to manufacture or import medicinal herbs in the EU. (Our Quality Services page outlines GMP audit and authorisation support.)
• Medical Writing & CTD Authoring: Crafting well-structured summaries (like the Herbal Expert Report or Clinical Overview) is a specialised task. Our Medical Writing team, experienced in CTD documentation for herbal, human, veterinary, and cosmetic products, takes on writing the quality overall summary, safety overview, and other required documents. We also handle Readability User Testing of leaflets – performance of Readability User Testing is a listed service. (See our Medical Writing Services page for how we approach CTD writing and readability tests.)
• Cosmetics & Food Supplements Regulatory Support: If through our borderline assessment we determine your product should remain a food supplement or cosmetic, we do not leave you without guidance. We have a Cosmetics Regulatory Services team that can help with Cosmetic Product Safety Reports and CPNP notifications, and we advise on food supplement compliance (permitted ingredients, nutrition claims, labelling under food law). This holistic approach means if a product shifts category, we still guide you – we are not strictly about making everything a medicine if it does not have to be. (Our Cosmetics page details compliance for personal care products.)
• Knowledge Centre & Training: We maintain resources on regulatory developments, such as changes in herbal legislation or new HMPC monographs. As part of our service, we often provide clients with training sessions – for example, a workshop on pharmacovigilance for their staff or a tutorial on GMP for botanical extracts. Our goal is not just one-off compliance but building your confidence in maintaining that compliance. (Future Knowledge Hub articles will include topics like “Traditional vs. Well-Established Use – Choosing the Path” and “Herbal Product Advertising: Staying Within the Law”.)